Drugs / Anvumetostat
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06333951 | Sep 2024 → Oct 2026 expected | non-small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06360354 | May 2024 → Oct 2026 expected | digestive system carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05975073 | Aug 2023 → Feb 2026 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT05094336 | Feb 2022 → Nov 2026 expected | — | Amgen | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06593522 | Dec 2024 → Oct 2026 expected | — | Amgen | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anvumetostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06333951 ↗ |
| Action | Inhibit | “MTA Cooperative PRMT5 inhibitor” NCT05094336 ↗ |
| Route | Oral | “Anvumetostat: Orally via tablet” NCT05094336 ↗ |
| Target | PRMT5 | “MTA Cooperative PRMT5 inhibitor” NCT05094336 ↗ |